MAZE THERAPEUTICS, INC. (MAZE) Net Margin
- 2026-03-31: Net Margin -121.04%.
- 2024-09-30: Net Margin -990.08%.
- 2024-06-30: Net Margin 84.28%.
Complete source-backed net margin history.
- Available history
- 2024-06-30 to 2026-03-31
- Data captured
Historical Net Margin
| Date | Net Margin |
|---|---|
| 2026-03-31 | -121.04% |
| 2024-09-30 | -990.08% |
| 2024-06-30 | 84.28% |
Annual Net Margin
| Date | Net Margin |
|---|---|
| 2024-12-31 | 31.18% |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |